EUVIMEDEUVIMED entdecken
Crossref

Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Iberdomide

Yiming Cheng, Allison Gaudy, Liangang Liu, Ying Ye, Michael Thomas, Yongjun Xue, Simon Zhou, Yan Li

Clinical Pharmacology in Drug Development · 2023-08 · 12 (8) · 819-825

DOI: 10.1002/cpdd.1254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 20.04.2023. Verfasst von Yiming Cheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA. Hauptthemen laut MEDLINE: Fluoroquinolones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Iberdomide is an orally available cereblon‐modulating agent being developed for the treatment of hematologic malignancies and autoimmune‐mediated diseases. To assess the potential concentration‐QTc relationship in humans and to ascertain or exclude a potential QT effect by iberdomide, a plasma concentration and ΔQTcF (change from baseline of corrected QT interval using the Fridericia formula) model of iberdomide was developed. Iberdomide concentration and paired high‐quality, intensive electrocardiogram signal from a single‐ascending‐dose study in healthy subjects ( N = 56) were included in the analysis. The primary analysis was based on a linear mixed‐effect model with ΔQTcF as the dependent variable; iberdomide plasma concentration and baseline QTcF as continuous covariates; treatment (active or placebo) and time as a categorical factor; and a random intercept per subject. The predicted change from baseline and placebo corrected (ΔΔQTcF) at the observed geometric mean maximum plasma concentration and 2‐sided 90% confidence intervals at different dose levels were calculated. The upper bound of the 90% confidence interval of the model‐predicted ΔΔQTcF effect at maximum concentration from the supratherapeutic dose of 6 mg (2.54 milliseconds) is

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluoroquinolonesHumansMoxifloxacinDouble-Blind MethodHeart RateDose-Response Relationship, DrugMorpholinesPhthalimidesPiperidones

Stichwörter der Autor:innen

QT prolongation effectcardiovascular assessmentiberdomide

Substanzen

MoxifloxacinFluoroquinolonesiberdomideMorpholinesPhthalimidesPiperidones

Autor:innen und Institutionen

  • Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Nonclinical Research & Development, Bristol Myers Squibb, Princeton, New Jersey, USA.

Zitieren

APA

Cheng, Y., Gaudy, A., Liu, L., Ye, Y., Thomas, M., Xue, Y., Zhou, S., & Li, Y. (2023). Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Iberdomide. Clinical Pharmacology in Drug Development, 12(8), 819-825. https://doi.org/10.1002/cpdd.1254

Vancouver

Cheng Y, Gaudy A, Liu L, Ye Y, Thomas M, Xue Y, et al. Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Iberdomide. Clinical Pharmacology in Drug Development. 2023;12(8):819-825. doi:10.1002/cpdd.1254

BibTeX
@article{Cheng2023,
  author = {Cheng, Yiming and Gaudy, Allison and Liu, Liangang and Ye, Ying and Thomas, Michael and Xue, Yongjun and Zhou, Simon and Li, Yan},
  title = {Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Iberdomide},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2023},
  volume = {12},
  number = {8},
  pages = {819--825},
  doi = {10.1002/cpdd.1254}
}
Kostenlos starten →